Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 738

The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.

The Lancet Commission on prostate cancer: planning for the surge in cases

Open access
James, Nicholas D, Tannock, Ian, N'Dow, James, Feng, Felix, Gillessen, Silke, Ali, Syed Adnan, Trujillo, Blanca, Al-Lazikani, Bissan, Attard, Gerhardt, Bray, Freddie, Compérat, Eva, Eeles, Ros, Fatiregun, Omolara, Grist, Emily, Halabi, Susan, Haran, Áine, Herchenhorn, Daniel, Hofman, Michael S, Jalloh, Mohamed, Loeb, Stacy, MacNair, Archie, Mahal, Brandon, Mendes, Larissa, Moghul, Masood, Moore, Caroline, Morgans, Alicia, Morris, Michael, Murphy, Declan, Murthy, Vedang, Nguyen, Paul L, Padhani, Anwar, Parker, Charles, Rush, Hannah, Sculpher, Mark, Soule, Howard, Sydes, Matthew R, Tilki, Derya, Tunariu, Nina, Villanti, Paul, Xie, Li-Ping·2024·The Lancet

Abstract

Executive summaryProstate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers.In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy.Our findings suggest that the number of new cases annually will rise from 1•4 million in 2020 to 2•9 million by 2040.This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it.We have projected trends in the incidence of prostate cancer and related mortality (assuming no changes in treatment) in the next 10-15 years, and make recom mendations on how to deal with these issues.For the Commission, we established four working groups, each of which examined a different aspect of prostate cancer: epidemiology and future projected trends in cases, the diagnostic pathway, treatment, and management of advanced disease, the main problem for most men diagnosed with prostate cancer worldwide.Throughout we have separated problems in highincome countries (HICs) from those in lowincome and middle income countries (LMICs), although we acknowledge that this distinction can be an oversimplification (some rich patients in LMICs can access highquality care, whereas many patients in HICs, especially the USA, cannot because of inadequate insurance coverage).The burden of disease globally is already substantial, but options to improve care are already available at moderate cost.We found that late diagnosis is widespread worldwide, but especially in LMICs, where it is the norm.Early diagnosis improves prognosis and outcomes, and reduces societal and individual costs, and we recommend changes to the diagnostic pathway that can be immediately implemented.For men diagnosed with advanced disease, optimal use of available technologies, adjusted to the resource levels available, could produce improved outcomes.We also found that demographic changes (ie, changing age structures and increasing life expectancy) in LMICs will drive big increases in prostate cancer, and cases are also projected to rise in highincome countries.This projected rise in cases has driven the main thrust of our recommendations throughout.Dealing with this rise in cases will require urgent and radical interventions, particularly in LMICs, including an emphasis on education (both of health professionals and the general population) linked to outreach programmes to increase awareness.If implemented, these inter ventions would shift the case mix from advanced to earlierstage disease, which in turn would necessitate different treatment approaches: earlier diagnosis would prompt a shift from palliative to curative therapies based around surgery and radiotherapy.Although ageadjusted mortality from prostate cancer is falling in HICs, it is rising in LMICs.And, despite large, well known differences in disease incidence and mortality by ethnicity (eg, incidence in men of African heritage is roughly double that in men of European heritage), most prostate cancer research has disproportionally focused on men of European heritage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)00651-2

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 159 references

Cited by

See all 738

Metadata

Authors
James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., Compérat, E., Eeles, R., Fatiregun, O., Grist, E., Halabi, S., Haran, Á., Herchenhorn, D., Hofman, M. S., Jalloh, M., Loeb, S., MacNair, A., Mahal, B., Mendes, L., Moghul, M., Moore, C., Morgans, A., Morris, M., Murphy, D., Murthy, V., Nguyen, P. L., Padhani, A., Parker, C., Rush, H., Sculpher, M., Soule, H., Sydes, M. R., Tilki, D., Tunariu, N., Villanti, P., & Xie, L.-P.
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-04
Volume
403
Issue
10437
Pages
1683-1722
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4393926609
Cited by
738
References
159
FWCI
188.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Lancet Commission on prostate cancer: planning for the surge in cases. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00651-2
The paper
James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., Compérat, E., Eeles, R., Fatiregun, O., Grist, E., Halabi, S., Haran, Á., Herchenhorn, D., Hofman, M. S., Jalloh, M., . . . Xie, L.-P. (2024). The Lancet Commission on prostate cancer: planning for the surge in cases. The Lancet. https://doi.org/10.1016/s0140-6736(24)00651-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.